Previous Article | Next Article ![]()
Infection and Immunity, October 1998, p. 4783-4787, Vol. 66, No. 10
Microbiology and Tumor Biology Center,
Received 9 March 1998/Returned for modification 4 May 1998/Accepted 16 July 1998
In this report, we show an age-related buildup of agglutinating
activity as well as serum activity against rosette formation in
children living in areas of Kenya and Gabon where malaria is endemic.
Sera from Kenyans in general exhibited a stronger and wider immune
response toward the epitopes, probably reflecting a difference in
transmission patterns between the two areas. Thus, our results indicate
that repeated malaria attacks in areas of endemicity, and consequently
exposure to different isolate-specific antigens, will elicit an
antibody-mediated response eventually enabling recognition of the
majority of rosetting and agglutinating antigens. The correlation
between antirosetting and agglutinating capacity was poor in individual
cases, indicating that the rosetting epitopes are only a minor part of
the highly diverse surface-exposed antigens (mainly PfEMP1) on the
surface of parasitized erythrocytes toward which antibodies may react.
These data together with our previous findings that the protection
against cerebral malaria correlates with presence of antirosetting
antibodies shed new light on our understanding of the gradual
acquisition of immunity toward severe complications of malarial
infection which children reared in areas of endemicity attain.
Acquired immunity to malaria
develops in individuals exposed to the parasite, but only after
repeated infection. Children are relatively protected during the first
months of life, but thereafter rapidly increasing parasite rates have
been noted. The mortality rate in areas of hyperendemicity is highest
during the first years of life, and by school age a considerable degree of immunity has already developed, with a high prevalence of
asymptomatic parasitemia (10, 31). However, persistence of
immunity requires repeated infections, and previously immune
individuals who have spent less than a year away from a malarious area
have been found to be susceptible to the disease (16, 37).
Thus, in areas of lower endemicity, with an unstable malaria situation,
the immunity of the population is low, and clinical malaria as well as
severe complications may occur in all age groups (54).
It is well established that humoral immunity, in addition to
cell-mediated immunity, is important in malaria, and passive transfer
of serum has been shown to have a protective or at least modifying
effect on the disease (17). Antibodies are directed either
against a number of identified proteins on the parasite itself or
against parasite-derived proteins expressed on the surface of the
infected erythrocyte (RBC) during intraerythrocytic development of
the parasite (26). It has been suggested that antibodies may
block the ligands involved in cytoadherence (47) and
also hinder merozoite reinvasion by binding to the merozoite surface, resulting in agglutination or blocking of the surface receptors involved in the penetration of erythrocytes (36, 53).
Several studies have demonstrated a high degree of serological
diversity of surface-exposed Plasmodium falciparum-induced antigens (19, 23, 27, 33), and antigenic variation has in
fact been reported for several malarial species (9, 22, 25,
35). Surface-exposed antigens undergo a rapid clonal variation in
vitro in the absence of immune pressure (41), and the PfEMP1 antigen, believed to play a major part in endothelial
cytoadherence, contributes substantially to this antigenic
variation (5, 6, 32). Recently it was established that
PfEMP1 is closely linked with expression of members of the large and
highly polymorphic family of var genes. Parasites
of variable immunological and adhesive phenotypes have been shown to
be correlated with switching events in this gene family
(45), which is a large and diverse array of genes dispersed
on several chromosomes, each gene encoding a 200- to 350-kDa protein.
The rate of var switching has been estimated to be as high
as 2.4% in P. falciparum (45).
Even though the antibody response to most parasite-derived antigens
probably plays no part in host defense, a correlation between
antibodies to surface-exposed antigens and protection against malarial
infection has been demonstrated (34). Investigators have
looked for a correlation between humoral immune response to
P. falciparum antigens and protection from severe
malarial disease but without success. Studies of Thai adults
(8) and Gambian children (18) have revealed no
differences in total antiparasite immunoglobulin G (IgG) titers between
patients with cerebral malaria and those with uncomplicated malaria.
Furthermore, the two groups were similar in the ability to agglutinate
parasite isolates, suggesting that they had had similar exposures to
malaria in the past (18).
We and others have previously described the rosetting phenomenon, i.e.,
the binding of uninfected RBC around infected ones (14, 20, 48,
50), and shown it to be a risk factor for the development of
severe malarial disease, e.g., cerebral malaria (13, 29, 40, 43,
46). Our previous results also indicate that exposure to the
rosetting epitopes and the resulting humoral immune response may confer
protection against cerebral disease. For example, when serum from a
patient was tested against the patient's own parasites, 17% of the
sera from children with cerebral malaria exhibited antirosetting
activity, while as many as 93% of the sera from children with
uncomplicated disease had the ability to disrupt rosettes in vitro
(13, 46).
In this study, we investigated the occurrence of antirosetting
antibodies in individuals living in areas holoendemic for P. falciparum malaria and their relation to age and the buildup of clinical immunity or semiimmunity in the population. In addition, we
studied the ability of the sera to agglutinate parasitized RBC (PRBC)
in order to confirm previous reports on a correlation between
antibodies to surface-exposed antigens and immunity to malaria and to
compare the expression of these two in vitro markers of immunity.
Patients and sera. (i) Kenyan material.
Human sera were
obtained during February to April from children aged 2 months to 15 years living in Saradidi, an area in western Kenya holoendemic for
malaria (4). The clinical status of the children was
assessed by physical examination at the Primary Health Care Station.
Only children without signs and symptoms of malaria were included in
the study. A small number of asymptomatic children had scanty
P. falciparum parasitemia.
(ii) Gabonese material.
Human sera were obtained during
April to June from children aged 2 months to 11 years attending
Hôpital Albert Schweitzer, Lambaréné, Gabon, an area
where malaria is predominantly hyperendemic (55). Only
children without P. falciparum parasites in peripheral blood smears and with no history of recent malarial infection were
included in the study. Sera were also obtained from 15 randomly chosen
adults living in the area and without a recent history of fever or
other signs of acute malarial infection.
Human serum IgG.
IgG was extracted from some of the patient
sera by using protein A-Sepharose as described elsewhere
(51).
Parasites.
Blood was drawn from the individuals included in
the studies. Parasites were cultivated according to standard procedures
as described elsewhere (14). Fifteen fresh and rosetting
P. falciparum isolates were obtained from Gabonese
patients with signs and symptoms of acute malaria. Assays were
performed when the parasites had reached the trophozoite stage during
the first cycle in culture. Gabonese isolate G168 was stored in liquid
nitrogen before use in the second set of assays. In addition, two
highly rosetting laboratory-propagated P. falciparum
strains and clones were used for testing the Kenyan sera: FCR3S1,
derived from strain FCR3 (formerly known as R+PA1) and
TM284 (isolated in Thailand). Only blood group O RBC were used in the
assays.
Rosette disruption assay.
Aliquots (12.5 to 25 µl) of
parasite cultures (FCR3S1, TM284, and wild isolates) were mixed
with equal amounts of human sera diluted in RPMI 1640 at end dilutions of 1:10 (Kenyan sera) and 1:5 (Gabonese sera) in a
96-well microtiter plate. After incubation for 30 min at 37°C,
rosetting was assessed as described previously (14). In
brief, the rosetting rate, expressed as the number of infected RBC in
rosettes relative to the total number of late-stage-infected RBC, was
compared to the rosetting rate of culture mixed with controls.
Agglutination assay.
Agglutination of PRBC was assayed as
described by Aguiar et al. (1), with some modifications.
PRBC cultured to late trophozoite and/or early schizont stages were
washed three times in malaria culture medium (RPMI 1640-HEPES, 25 mM
sodium bicarbonate, 10 µg of gentamicin per ml) and then resuspended
at 20% hematocrit. Aliquots of 25 µl were dispensed in polystyrene
round-bottom tubes. An equal volume of prediluted serum (end dilutions
of 1:10 and 1:5) was added to the parasite culture. The PRBC-serum
mixture was then incubated at 37°C for 1 h with constant
rotation at 3 rpm. From each polystyrene tube, an aliquot mixed with a
small amount of acridine orange was mounted on a glass slide and 50 consecutive fields of vision were counted diagonally, using a 40× lens
and incident UV light microscopy as described elsewhere (14). Control sera from healthy Swedish blood donors or from a Liberian hyperimmune donor were used. Results of the agglutination assay were scored on a semiquantitative scale as negative (no agglutinates of When sera from Kenyan children were tested against the two
laboratory strains and clones, we found a significant correlation between various age groups of children and the occurrence of
antirosetting serum activity in each group (FCR3S1, r = 0.98; TM284, r = 0.96 [Fig.
1A]). While no children below 2 years of
age exhibited
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Age-Related Buildup of Humoral Immunity against Epitopes for
Rosette Formation and Agglutination in African Areas of
Malaria Endemicity
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
70°C and heat inactivated at 56°C before use in the
assays. Control sera were obtained from healthy Swedish blood donors.
Hyperimmune serum from a Liberian donor (BD245) was also used.
4 PRBC), 1+ (1 to 5 agglutinates of 4 to 10 PRBC), 2+
(>5 agglutinates of 4 to 10 PRBC or 1 to 5 agglutinates of 11 to 20 PRBC), 3+ (>5 agglutinates of 11 to 20 PRBC or 1 to 5 agglutinates of
>20 PRBC), or 4+ (>5 agglutinates of >20 PRBC).
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
50% antirosetting serum activity, a high percentage of
children
14 years of age had such activity: 60% against strain
FCR3S1 and 100% against TM284.

View larger version (31K):
[in a new window]
FIG. 1.
Percentage of Kenyan individuals in each age group
exhibiting
50% antirosetting serum activity (A) and agglutination
(
1+ on the semiquantitative scale) (B) toward the P. falciparum laboratory strain FCR3S1 (
) or TM284 (
). Sera
from 22 to 24 individuals in each age group were tested in assays
performed as indicated in Materials and Methods.
A positive agglutination activity, defined as
1+ on the
semiquantitative scale, was found in many individuals in the lower age
groups and increased to 75 to 80% (for FCR3S1) and 100% (for TM284)
of individuals
12 years. When strain TM284 was tested, a strong and
significantly positive correlation between age and the agglutinating
ability of the sera was exhibited (r = 0.78 [Fig.
1B]). For strain FCR3S1, on the other hand, a steep increase of the
number of sera with positive agglutinating activity was found in
children up to 8 to 9 years of age, followed by a steady state of
somewhat lower percentages at higher ages (10 to 15 years; [Fig.
1B]). Even though both phenomena were significantly correlated with
age, only a weak or even no correlation was found between the
expression of antirosetting activity and agglutination on an individual
level (FCR3S1, r = 0.52; TM284, r = 0.36). Similarly, only a weak correlation was found between the
responses of the two strains tested; i.e., a serum with high
antirosetting activity toward TM284 did not necessarily react to
FCR3S1, and vice versa. The same was true for agglutination (data not
shown).
Twelve sera from Kenyan adolescents, selected for high antirosetting activity against any or both of the two laboratory strains and for a positive agglutinating response, were tested against Gabonese P. falciparum isolates. A similarly good and uniform recognition of rosetting epitopes in the Gabonese isolates was found, indicating extensive recognition by these sera of (all) rosetting epitopes in another geographical area of Africa (Fig. 2A). Also, the agglutinating activity was strong but more diverse, and two Gabonese isolates were poorly recognized by many Kenyan sera (Fig. 2B).
|
Similar but "reverse" crossover testing was done with 15 randomly
selected Gabonese adults against the two laboratory strains used in
Kenya (FCR3S1 and TM284) and against six wild isolates obtained in
Gabon (Fig. 3). The antirosetting
activity against the two laboratory strains was less intense than
expected for similar groups in Kenya, while the agglutinating activity
was more uniform and similar to the results obtained in Kenya. Fourteen of the fifteen Gabonese sera tested had an effect (
15% rosette reversion) on most strains and isolates tested, and seven of the tested
sera exhibited an antirosetting effect on all isolates. The different
isolates varied in their recognition by the different sera, but in
general the sera exhibited greater activity against the six wild
isolates than against the two laboratory test strains. The
agglutinating pattern was more uniform, with no significant differences
between wild isolates and laboratory strains, nor was there any obvious
correlation between antirosetting and agglutinating activities. One
individual, an adult of Gabonese origin, was totally negative for both
antirosetting and agglutinating activities toward all strains and
isolates.
|
Finally, when a lower number of sera from Gabonese children were tested
against the two laboratory strains and clones and against a Gabonese
isolate (G168), the buildup of agglutinating activity was similar to
that seen in the Kenyan samples (Fig. 4B). However, a much weaker buildup of
antirosetting activity was found toward the two laboratory
strains (Fig. 4A). In the highest age group, 9 to 11 years, only 30%
of the children exhibited activity toward either of the two
strains. However, when an isolate (G168) obtained in Gabon was
used, more than 55% in the higher age groups exhibited high
(
50%) antirosetting activity, and there was no
significant individual correlation between highly
antirosetting activity and agglutinating activity (r = 0.48).
|
Both the antirosetting activity and the ability to agglutinate PRBC were always contained in the immunoglobulin fraction when sera were fractionated on protein A-Sepharose.
| |
DISCUSSION |
|---|
|
|
|---|
In this report, we have shown an age-related increase of agglutinating activity in sera from children living in areas of Africa where malaria is endemic. Even though only two laboratory strains were used for testing, our results correspond well with those of previous studies that established a correlation between antibodies to surface-exposed antigens and immunity to malaria (34). Even more interesting, however, is the age-related buildup of serum activity against rosette formation seen in children living in areas of both Kenya and Gabon where malaria is endemic. Since both the antirosetting activity and the ability to agglutinate PRBC were always contained in the immunoglobulin fraction when serum and plasma samples were fractionated on protein A-Sepharose, we believe the activity to be antibody mediated rather than an effect of other serum components.
In areas with relatively high malarial transmission such as Kisumu and (to a somewhat lesser extent) Lambaréné, severe anemia is a common complication among young children but decreases with age (7, 12, 28). In other areas, cerebral malaria is the dominating severe complication in childhood. We have previously shown an association between rosetting and cerebral malaria and that protection against cerebral malaria correlates with the presence of antirosetting antibodies in serum (13, 46). Recently a similar association between rosetting and anemia was reported (39). These data exhibiting an age-related buildup of antirosetting antibodies are thus well in accordance with previous reports on rosetting and consistent with the clinical situation where a gradual acquisition of immunity toward severe complications of P. falciparum infection is seen in children reared in areas of endemicity.
In Gabon, this buildup of humoral immunity could be seen only when a locally obtained wild isolate was used, and the response to the two laboratory strains was much less pronounced than in Kenya. This somewhat weaker response was confirmed when sera from Gabonese adults were tested against indigenous isolates. While the recognition of rosetting epitopes in some isolates was high, the response toward other isolates was weaker and more diverse. In addition, sera from Kenyans with high antirosetting activity also recognized all of the Gabonese strains against which they were tested. This discrepancy may reflect a difference in transmission patterns between the two areas. Malaria is holoendemic in the Kisumu area, with peak entomological inoculation rates of one infective bite per person every two nights (4) and 85 to 95% P. falciparum prevalence during the high-transmission season in April (3). The transmission in the Lambaréné area is less intense, with seasonal variations and peak P. falciparum prevalence of 50 to 60% in November (30, 55).
The difference in response between the various P. falciparum strains and isolates tested probably reflects the high degree of serotypical and cytoadherent hypervariability of surface-exposed P. falciparum induced antigens, in particular PfEMP1, known to exist (19, 23, 27, 33) as well as the variability in the expression of rosetting ligands (rosettins) previously described (14, 21, 24, 52).
Antigenic variation is, indeed, a feature of the parasite worldwide (1, 11, 38, 49). Our results indicate that repeated malaria attacks in areas of endemicity, and consequently exposure to different isolate-specific antigens, will elicit an antibody-mediated response eventually enabling recognition of the majority of rosetting and agglutinating antigens. This age-related immune response may contribute to protective immunity.
Interestingly, antirosetting activity correlated poorly with agglutinating activity in individual sera. Other investigators have found a weak correlation between the two activities among highly exposed adults (42). Recent in vitro findings indicate that both rosetting and cytoadherence properties may well be linked to the same family of molecules, PfEMP1 (2, 15, 44, 45). Though PfEMP1 was first ascribed importance only for cytoadherence and serotypical variation, very recent studies have reported evidence that PfEMP1 is also involved in rosetting. We have provided evidence that PfEMP1 can bind to heparan sulfate, an interaction that proved to be sensitive to disruption with heparin as well as with heparan sulfate but not with other glycosaminoglycans tested (15). In another study that ascribed to PfEMP1 importance for rosetting, it was found that complement receptor 1 constituted the ligand on noninfected RBC (44). The weak correlation, or even absence of correlation, between antirosetting activity and agglutinating capacity found in this (and other) studies is not necessarily in contrast with the in vitro findings but may well be explained by the fact that the rosetting epitopes are only part of the highly diverse PfEMP1 molecule and thus only a minor part of the highly diverse surface-exposed antigens on the surface of parasitized erythrocytes toward which antibodies may react.
| |
ACKNOWLEDGMENTS |
|---|
We thank all persons participating in this study, the staff at KEMRI, Kisumu, Kenya, and Laboratoire de Recherches, Hôpital du Docteur Albert Schweitzer, Lambaréné, Gabon, for invaluable help, L. Gregory for skillful technical assistance, and M. Schlichtherle for editorial comments.
This study was supported by the Swedish Medical Research Council and the Swedish Society of Medicine.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Epidemiology, Swedish Institute for Infectious Disease Control, 105 21 Stockholm, Sweden. Phone: 46 8 735 1063. Fax: 46 8 735 11 77. E-mail: johan.carlson{at}smi.ki.se.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aguiar, J. C., G. R. Albrecht, P. Cegielski, B. M. Greenwood, K. B. Jensen, G. Lallinger, A. Martinez, I. A. McGregor, J. N. Minjas, J. Neequaye, M. E. Patarroyo, J. A. Sherwood, and R. J. Howard. 1992. Agglutination of Plasmodium falciparum-infected erythrocytes from East and West African isolates by human sera from distinct geographic regions. Am. J. Trop. Med. Hyg. 47:621-632. |
| 2. | Baruch, D. I., B. L. Pasloske, H. B. Singh, X. Bi, X. C. Ma, M. Feldman, T. F. Taraschi, and R. J. Howard. 1995. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82:77-87[Medline]. |
| 3. | Beach, R. F., T. K. Ruebush, J. D. Sexton, P. L. Bright, A. W. Hightower, J. G. Breman, D. L. Mount, and A. J. Oloo. 1993. Effectiveness of permethrin-impregnated bed nets and curtains for malaria control in a holoendemic area of Western Kenya. Am. J. Trop. Med. Hyg. 49:290-300. |
| 4. | Beier, J. C., P. V. Perkins, F. K. Onyango, T. P. Gargan, C. N. Oster, R. E. Whithmire, D. K. Koech, and C. R. Roberts. 1990. Characterization of malaria transmission by Anopheles (Diptrea: Culicidae) in Western Kenya in preparation for malaria vaccine trials. J. Med. Entomol. 27:570-577[Medline]. |
| 5. | Berendt, A. R., D. J. P. Ferguson, and C. I. Newbold. 1990. Sequestration in Plasmodium falciparum malaria: sticky cells and sticky problems. Parasitol. Today 6:247-254. [Medline] |
| 6. |
Biggs, B.-A.,
L. Gooze,
K. Wycherley,
W. Wollish,
B. Southwell,
J. H. Leech, and G. V. Brown.
1991.
Antigenic variation in Plasmodium falciparum.
Proc. Natl. Acad. Sci. USA
88:9171-9174 |
| 7. | Branch, O. H., V. Udhayakumar, A. W. Hightower, A. J. Oloo, W. A. Hawley, B. L. Nahlen, P. B. Bloland, D. C. Kaslow, and A. A. Lal. 1998. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: association with febrile illness, parasitemia and anemia. Am. J. Trop. Med. Hyg. 58:211-219[Abstract]. |
| 8. |
Brasseur, P.,
J. J. Ballet, and P. Druilhe.
1990.
Impairment of Plasmodium falciparum-specific antibody response in severe malaria.
J. Clin. Microbiol.
28:265-268 |
| 9. | Brown, K. N., and I. N. Brown. 1965. Immunity to malaria: antigenic variation in chronic infections of Plasmodium knowlesi. Nature 208:1286-1288[Medline]. |
| 10. | Bruce-Chwatt, L. J. 1952. Malaria in African infants and children in southern Nigeria. Ann. Trop. Med. Parasitol. 46:173-200[Medline]. |
| 11. | Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and K. Marsh. 1998. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4:358-360[Medline]. |
| 12. | Burchard, G. D., P. Radloff, J. Philipps, J. Knobloch, and P. G. Kremsner. 1995. Increased erythropoietin production in children with severe malarial anemia. Am. J. Trop. Med. Hyg. 53:547-551. |
| 13. | Carlson, J., H. Helmby, A. V. Hill, D. Brewster, B. M. Greenwood, and M. Wahlgren. 1990. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet 336:1457-1460[Medline]. |
| 14. |
Carlson, J.,
G. Holmquist,
D. W. Taylor,
P. Perlmann, and M. Wahlgren.
1990.
Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes.
Proc. Natl. Acad. Sci. USA
87:2511-2515 |
| 15. |
Chen, Q.,
A. Barragan,
V. Fernandez,
A. Sundström,
M. Schlichtherle,
A. Sahlén,
J. Carlson,
S. Datta, and M. Wahlgren.
1998.
Identification of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) as the rosetting ligand of the malaria parasite P. falciparum.
J. Exp. Med.
187:1-9 |
| 16. | Cohen, S., and P. H. Lambert. 1982. Malaria, p. 422-438. In S. Cohen, and D. Warren (ed.), Immunology of parasitic infections, 2nd ed. Blackwell, London, England. |
| 17. | Cohen, S., I. A. McGregor, and S. Carrington. 1961. Gammaglobulin and acquired immunity to human malaria. Nature 192:733-737[Medline]. |
| 18. | Erunkulu, O. A., A. V. Hill, D. P. Kwiatkowski, J. E. Todd, J. Iqbal, K. Berzins, E. M. Riley, and B. M. Greenwood. 1992. Severe malaria in Gambian children is not due to lack of previous exposure to malaria. Clin. Exp. Immunol. 89:296-300[Medline]. |
| 19. | Forsyth, K. P., G. Philip, T. Smith, E. Kum, B. Southwell, and G. V. Brown. 1989. Diversity of antigens expressed on the surface of the erythrocytes infected with mature Plasmodium falciparum parasites in Papua New Guinea. Am. J. Trop. Med. Hyg. 41:259-265. |
| 20. | Handunnetti, S. M., P. H. David, K. L. R. L. Perera, and K. N. Mendis. 1989. Uninfected erythrocytes from "rosettes" around Plasmodium falciparum infected erythrocytes. Am. J. Trop. Med. Hyg. 40:115-118. |
| 21. |
Handunnetti, S. M.,
A. D. Gilladoga,
M.-R. van Schravendijk,
K. Nakomura,
M. Aikawa, and R. J. Howard.
1992.
Purification and in vitro selection of rosette-positive (R+) and rosette-negative (R ) phenotypes of knob-positive Plasmodium falciparum parasites.
Am. J. Trop. Med. Hyg.
46:371-381.
|
| 22. |
Handunnetti, S. M.,
K. N. Mendis, and P. H. David.
1987.
Antigenic variation of cloned Plasmodium fragile in its natural host Macaca sinica. Sequential appearance of successive variant antigenic types.
J. Exp. Med.
165:1269-1283 |
| 23. |
Hasler, T.,
S. H. Handunetti,
J. C. Aguiar,
M. R. van Schravendijk,
B. M. Greenwood,
G. Lallinger,
P. Cegielski, and R. J. Howard.
1990.
In vitro rosetting, cytoadherence, and microagglutination of Plasmodium falciparum-infected erythrocytes from Gambian and Tanzanian patients.
Blood
76:1845-1852 |
| 24. | Helmby, H., L. Cavelier, U. Petterson, and M. Wahlgren. 1993. Rosetting Plasmodium falciparum-infected erythrocytes express unique antigens on their surface. Infect. Immun. 61:284-288. |
| 25. |
Hommell, M.,
P. H. David, and L. D. Oligino.
1983.
Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity and the role of the spleen.
J. Exp. Med.
157:1137-1148 |
| 26. | Hommel, M., and S. Semoff. 1988. Expression and function of erythrocyte-associated surface antigens in malaria. Biol. Cell 64:183-203[Medline]. |
| 27. | Iqbal, J., P. Perlmann, and K. Berzins. 1993. Serologic diversity of antigens expressed on the surface of Plasmodium falciparum infected erythrocytes in Punjab (Pakistan). Trans. R. Soc. Trop. Med. Hyg. 87:583-588[Medline]. |
| 28. | Kitua, A. Y., T. A. Smith, P. L. Alonso, H. Urassa, H. Masanja, J. Kimario, and M. Tanner. 1997. The role of low level Plasmodium falciparum parasitemia in anaemia among infants living in an area of intense and perennial transmission. Trop. Med. Int. Health 2:325-333[Medline]. |
| 29. | Kun, J., R. Schmidt-Ott, L. Lehman, B. Lell, D. Luckner, B. Greve, P. Matousek, and P. Kremsner. 1998. Merozoite surface antigen 1 and 2 genotypes and rosetting of Plasmodium falciparum in severe and mild malaria in Lambaréné, Gabon. Trans. R. Soc. Trop. Med. Hyg. 92:110-114[Medline]. |
| 30. | Lell, B., D. Luckner, M. Ndjavé, T. Scott, and P. Kremsner. 1998. Randomised placebo-controlled study of atovaquone and proguanil for malaria prophylaxis. Lancet 351:709-713[Medline]. |
| 31. | Lucas, A. O., R. G. Hendrickse, O. A. Okubadejo, W. H. G. Richards, R. A. Neal, and B. A. K. Kofie. 1969. The suppression of malarial parasitaemia by pyrimethamine in combination with dapsone or sulphormethoxine. Trans. R. Soc. Trop. Med. Hyg. 63:216-229[Medline]. |
| 32. |
Magowan, C.,
W. Wollish,
L. Anderson, and J. Leech.
1988.
Cytoadherence by Plasmodium falciparum-infected erythrocytes is correlated with the expression of a family of variable proteins on infected erythrocytes.
J. Exp. Med.
168:1307-1320 |
| 33. |
Marsh, K., and R. J. Howard.
1986.
Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants.
Science
231:150-153 |
| 34. | Marsh, K., L. Otoo, R. J. Hayes, D. C. Carson, and B. M. Greenwood. 1989. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83:293-303[Medline]. |
| 35. | McLean, S. A., C. D. Pearson, and R. S. Phillips. 1982. Plasmodium chabaudi: evidence of antigenic variation during recrudescent parasitaemias in mice. Exp. Parasitol. 54:296-302[Medline]. |
| 36. |
Miller, L. H.,
M. Aikawa, and J. A. Dvorak.
1975.
Malaria (Plasmodium knowlesi) merozoites: immunity and the surface coat.
J. Immunol.
114:1237 |
| 37. | Neva, F. A. 1977. Looking back for a view of the future: observations of immunity to induce malaria. Am. J. Trop. Med. Hyg. 26:211-215. |
| 38. | Newbold, C. I., R. Pinches, D. J. Roberts, and K. Marsh. 1992. Plasmodium falciparum: the human agglutinating antibody response to the infected red cell surface is predominantly variant specific. Exp. Parasitol. 75:281-292[Medline]. |
| 39. | Newbold, C. I., P. Warn, G. Black, A. Berendt, A. Craig, B. Snow, M. Msobo, N. Peshu, and K. Marsh. 1997. Receptor-specific adhesion and clinical disease in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 57:389-398. |
| 40. |
Ringwald, P.,
F. Peyron,
J. P. Lepers,
P. Rabarison,
C. Rakotomalala,
M. Razanamparany,
M. Rabodonirina,
J. Roux, and J. Le Bras.
1993.
Parasite virulence factors during falciparum malaria: rosetting, cytoadherence, and modulation of cytoadherence by cytokines.
Infect. Immun.
61:5198-5204 |
| 41. | Roberts, D. J., A. G. Craig, A. R. Berendt, R. Pinches, G. Nash, K. Marsh, and C. I. Newbold. 1992. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 357:689-692[Medline]. |
| 42. | Rogerson, S. J., H. P. Beck, F. Al-Yaman, B. Currie, M. P. Alpers, and G. V. Brown. 1996. Disruption of erythrocyte rosettes and agglutination of erythrocytes infected with Plasmodium falciparum by the sera of Papua New Guineans. Trans. R. Soc. Trop. Med. Hyg. 90:80-84[Medline]. |
| 43. | Rowe, A., J. Obeiro, C. I. Newbold, and K. Marsh. 1995. Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect. Immun. 63:2323-2326[Abstract]. |
| 44. | Rowe, J. A., J. M. Moulds, C. I. Newbold, and L. H. Miller. 1997. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 388:292-295[Medline]. |
| 45. | Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. Hudson-Taylor, D. S. Peterson, R. Pinches, C. I. Newbold, and L. H. Miller. 1995. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82:101-110[Medline]. |
| 46. | Treutiger, C. J., I. Hedlund, H. Helmby, J. Carlson, A. Jepson, P. Twumasi, D. Kwiatkowski, B. M. Greenwood, and M. Wahlgren. 1992. Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am. J. Trop. Med. Hyg. 46:503-510. |
| 47. | Udeinya, I. J., L. H. Miller, I. A. McGregor, and J. B. Jensen. 1983. Plasmodium falciparum strain-specific antibody blocks binding of infected erythrocytes to amelanotic melanoma cells. Nature 303:429-431[Medline]. |
| 48. |
Udomsangpetch, R.,
B. Wåhlin,
J. Carlson,
K. Berzins,
M. Torii,
M. Aikawa,
P. Perlmann, and M. Wahlgren.
1989.
Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte rosettes.
J. Exp. Med.
169:1835-1840 |
| 49. |
van Schravendijk, M.-R.,
E. P. Rock,
K. Marsh,
Y. Ito,
M. Aikawa,
J. Neequaye,
D. Ofori-Adjei,
R. Rodriguez,
M. E. Patarroyo, and R. J. Howard.
1991.
Characterization and localization of Plasmodium falciparum surface antigens on infected erythrocytes from West African patients.
Blood
78:226-236 |
| 50. | Wahlgren, M. 1986. Doctoral thesis. Karolinska Institutet, Stockholm, Sweden. |
| 51. | Wahlgren, M., J. Carlson, W. Ruangjirachuporn, D. Conway, H. Helmby, M. E. Patarroyo, A. Martinez, and E. Riley. 1990. Geographical distribution of Plasmodium falciparum erythrocyte rosetting and frequency of rosetting antibodies in human sera. Am. J. Trop. Med. Hyg. 43:333-338. |
| 52. | Wahlgren, M., V. Fernandez, C. Scholander, and J. Carlson. 1994. Rosetting. Parasitol. Today 10:73-79. [Medline] |
| 53. |
Wåhlin, B.,
M. Wahlgren,
H. Perlmann,
K. Berzins,
A. Björkman,
M. E. Patarroyo, and P. Perlmann.
1984.
Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibiting merozoite invasion.
Proc. Natl. Acad. Sci. USA
81:7912-7916 |
| 54. | Wilding, E., S. Winkler, P. G. Kremsner, C. Brandts, L. Jenne, and W. H. Wernsdorfer. 1995. Malaria epidemiology in the province of Moyen Ogooué, Gabon. Trop. Med. Parasitol. 46:77-82[Medline]. |
| 55. | World Health Organization. 1990. Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg. 84:(Suppl. 2):1-65. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|